NCT02265341View on ClinicalTrials.gov

Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

May 1, 2018

Study Completion Date

June 14, 2019

Conditions
Malignant Hepatobiliary Neoplasm
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Ponatinib Hydrochloride

Given PO

OTHER

Quality-of-Life Assessment

Ancillary studies

Trial Locations (1)

85259

Mayo Clinic in Arizona, Scottsdale

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER